Japanese Encephalitis (JE) is a flavivirus that remains a serious health problem across Asia, predominantly affecting people living in affected areas, but also infecting tourists and military personnel travelling to endemic regions. Every year, the virus infects approximately 30,000 to 50,000 people causing 10,000 to 30,000 deaths and around 50% of the cases result in permanent neurological disabilities. Vaxine has developed a new high potency vaccine based on the combination of cell-culture JE antigen combined with Advax™ adjuvant. In animal studies this vaccine demonstrated superior protection against JE also also cross-protection against other related flavivirus infections including West Nile Virus, Kunjin and Murray Valley Encephalitis. Vaxine currently plans to commence a phase I human clinical trial of an Advax™-adjuvanted Japanese Encephalitis vaccine in 2016.